Background and Purpose: Early neurological deterioration (END) occurs in 10-40% of acute ischemic stroke (AIS) patients and has been associated with worse outcome. Recent improvements in treatment may have reduced the prevalence of END. A single early control or repeated observations have been applied to detect END close to occurrence, in order to improve the poor outcome associated with END, as clinical interventions may still be effective. Deterioration detected through repeated observations may be transitory or lead to END. Our aim was to study outcome after END and transitory deterioration (TD). Methods: In acute ischemic stroke patients, key Scandinavian Stroke Scale (SSS) items were scored 12 times from admission to 72 h. END was defined as ≥2 point decrease in any key SSS item from admission to 72 h. Early deterioration episode was defined as similar worsening between two consecutive assessments within 72 h, and TD as early deterioration episode in patients without END. Main outcome measures were odds ratios (OR) for worse functional outcome (including death) measured by modified Rankin scale at 90 days for END and TD compared with stable patients. Results: 368 patients were included. 13.9% had END and 28.3% had TD. Both deterioration groups were associated with worse outcome at 12 weeks compared with stable patients, with ORs of 35.1 (95% CI 8.8-140) for death/dependency and 5.8 (95% CI 1.8-19.4) for death in END patients and ORs of 2.3 (95% CI 1.1-4.8) for death/dependency and 1.9 (95% CI 0.5-6.3) for death in patients with TD. LOS increased by 6.4 days for END (p < 0.001) and 1.1 days for TD (p = 0.014) compared with stable patients. Conclusion: We found a strong association between END and worse outcome, and even TD doubled the OR for death/dependency compared to stable patients. Early deterioration episodes identified through frequent observations are therefore clinically significant and such frequent observations may detect worsening sufficiently close to occurrence for potentially effective treatment to be applied.

Keywords:
Acute ischemic stroke, Complications, Early neurological deterioration, Stroke scales, Clinical diagnosis, Prognosis
1.
Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis 1999;9(suppl 3):1-8.
2.
Birschel P, Ellul J, Barer D: Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis 2004;17:242-252.
3.
Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC; German Stroke Study Collaboration: Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005;62:393-397.
4.
Rödén-Jüllig A, Britton M: Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Inter Med 2000;248:287-291.
5.
Kwan J, Hand P: Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome. QJM 2006;99:625-633.
6.
Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156-159.
7.
Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ: Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004;35:1421-1425.
8.
Indredavik B, Rohweder G, Naalsund E, Lydersen S: Medical complications in a comprehensive stroke unit and an early supported discharge service. Stroke 2008;39:414-420.
9.
Govan L, Langhorne P, Weir CJ; Stroke Unit Trialists Collaboration: Does the prevention of complications explain the survival benefit of organized inpatient (stroke unit) care?: further analysis of a systematic review. Stroke 2007;38:2536-2540.
10.
Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC, Martin-Schild S: What change in the national institutes of health stroke scale should define neurologic deterioration in acute ischemic stroke? J Stroke Cerebrovasc Dis 2013;22:675-682.
11.
Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J: Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 1999;30:2631-2636.
12.
Siegler JE, Martin-Schild S: Daily National Institutes of Health Stroke Scale examinations at stroke centers: why not do them? Int J Stroke 2015;10:140-142.
13.
Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim LL, Holme I: Benefit of a stroke unit: a randomized controlled trial. Stroke 1991;22:1026-1031.
14.
Indredavik B, Fjaertoft H, Ekeberg G, Løge AD, Mørch B: Benefit of an extended stroke unit service with early supported discharge: a randomized, controlled trial. Stroke 2000;31:2989-2994.
15.
Indredavik B, Bakke F, Slordahl SA, Rokseth R, Hâheim LL: Treatment in a combined acute and rehabilitation stroke unit: which aspects are most important? Stroke 1999;30:917-923.
16.
Helleberg B, Ellekjær H, Rohweder G, Indredavik B: Mechanisms, predictors and clinical impact of early neurological deterioration: the protocol of the Trondheim early neurological deterioration study. BMC Neurol 2014;14:201.
17.
Thanvi B, Treadwell S, Robinson T: Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management. Postgrad Med J 2008;84:412-417.
18.
Serena J, Rodríguez-Yáñez M, Castellanos M: Deterioration in acute ischemic stroke as the target for neuroprotection. Cerebrovasc Dis 2006;21(suppl 2):80-88.
19.
Barber M, Stott DJ, Langhorne P: An internationally agreed definition of progressing stroke. Cerebrovasc Dis 2004;18:255-256.
20.
Barber M, Wright F, Stott DJ, Langhorne P: Predictors of early neurological deterioration after ischaemic stroke: a case-control study. Gerontology 2004;50:102-109.
21.
Saver JL, Altman H: Relationship between neurologic deficit severity and final functional outcome shifts and strengthens during first hours after onset. Stroke 2012;43:1537-1541.
22.
Siegler JE, Boehme AK, Albright KC, George AJ, Monlezun DJ, Beasley TM, et al: A proposal for the classification of etiologies of neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e549-e556.
23.
Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R: ‘Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53:309-315.
24.
Rohweder G, Ellekjær H, Salvesen Ø, Naalsund E, Indredavik B: Functional outcome after common poststroke complications occurring in the first 90 days. Stroke 2015;46:65-70.
25.
Oldenbeuving AW, de Kort PL, Jansen BP, Algra A, Kappelle LJ, Roks G: Delirium in the acute phase after stroke: incidence, risk factors, and outcome. Neurology 2011;76:993-999.
26.
Fong TG, Tulebaev SR, Inouye SK: Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol 2009;5:210-220.
27.
Alvarez FJ, Segura T, Castellanos M, Leira R, Blanco M, Castillo J, et al: Cerebral hemodynamic reserve and early neurologic deterioration in acute ischemic stroke. J Cereb Blood Flow Metab 2004;24:1267-1271.
28.
Röden-Jüllig A, Britton M, Gustafsson C, Fugl-Meyer A: Validation of four scales for the acute stage of stroke. J Int Med 1994;236:125-136.
29.
Lyden P, Raman R, Liu L, Emr M, Warren M, Marler J: National Institutes of Health Stroke Scale certification is reliable across multiple venues. Stroke 2009;40:2507-2511.
30.
Josephson SA, Hills NK, Johnston SC: NIH Stroke Scale reliability in ratings from a large sample of clinicians. Cerebrovasc Dis 2006;22:389-395.
31.
Terwee C, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al: Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.